References
- Robert C, Schachter J, Long G V, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med 2015; 372:2521-32; http://www.ncbi.nlm.nih.gov/pubmed/25891173;PMID:25891173; http://dx.doi.org/10.1056/NEJMoa1503093
- Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, Thompson CB, Bluestone J a. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994; 1:405-13; PMID:7882171; http://dx.doi.org/10.1016/1074-7613(94)90071-X
- Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 1991; 174:561-9; http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2118936&tool=pmcentrez&rendertype=abstract; PMID:1714933; http://dx.doi.org/10.1084/jem.174.3.561
- Krummel M, Allison J. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 1995; 182:459-65; http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2192127&tool=pmcentrez&rendertype=abstract; PMID:7543139; http://dx.doi.org/10.1084/jem.182.2.459
- Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23; http://www.ncbi.nlm.nih.gov/pubmed/20525992; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466
- Laurent S, Queirolo P, Boero S, Salvi S, Piccioli P, Boccardo S, Minghelli S, Morabito A, Fontana V, Pietra G et al. The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-α production. J Transl Med 2013; 11:108; http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3663700&tool=pmcentrez&rendertype=abstract; PMID:23634660; http://dx.doi.org/10.1186/1479-5876-11-108
- Weber JS, Hamid O, Chasalow SD, Wu DY, Parker SM, Galbraith S, Gnjatic S, Berman D. Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma. J Immunother 2012; 35:89-97; http://www.ncbi.nlm.nih.gov/pubmed/22130166; PMID:22130166; http://dx.doi.org/10.1097/CJI.0b013e31823aa41c
- Tarhini AA, Edington H, Butterfield LH, Lin Y, Shuai Y, Tawbi H, Sander C, Yin Y, Holtzman M, Johnson J et al. Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. PLoS One 2014; 9:e87705; http://dx.plos.org/10.1371/journal.pone.0087705;
- Hodi FS, Butler M, Oble D a, Seiden MV, Haluska FG, Kruse A, Macrae S, Nelson M, Canning C, Lowy I et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A 2008; 105:3005-10; http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2268575&tool=pmcentrez&rendertype=abstract; PMID:18287062; http://dx.doi.org/10.1073/pnas.0712237105
- Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, Walsh LA, Postow MA, Wong P, Ho TS et al. Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma. N Engl J Med 2014; 141119140020009; http://www.nejm.org/doi/abs/10.1056/NEJMoa1406498; PMID:25409260; http://dx.doi.org/10.1056/NEJMoa1406498
- Klein O, Ebert LM, Nicholaou T, Browning J, Russell SE, Zuber M, Jackson HM, Dimopoulos N, Tan BS, Hoos A et al. Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4. Clin Cancer Res 2009; 15:2507-13; http://www.ncbi.nlm.nih.gov/pubmed/19318477; PMID:19318477; http://dx.doi.org/10.1158/1078-0432.CCR-08-2424
- Van Rooij N, van Buuren MM, Philips D, Velds A, Toebes M, Heemskerk B, van Dijk LJA, Behjati S, Hilkmann H, El Atmioui D et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol 2013; 31:e439-42; http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3836220&tool=pmcentrez&rendertype=abstract; PMID:24043743; http://dx.doi.org/10.1200/JCO.2012.47.7521
- O'Mahony D, Morris JC, Quinn C, Gao W, Wilson WH, Gause B, Pittaluga S, Neelapu S, Brown M, Fleisher T a et al. A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy. Clin Cancer Res 2007 13:958-64; http://www.ncbi.nlm.nih.gov/pubmed/17289891; PMID:17289891; http://dx.doi.org/10.1158/1078-0432.CCR-06-1974
- Meyer C, Cagnon L, Costa-Nunes CM, Baumgaertner P, Montandon N, Leyvraz L, Michielin O, Romano E, Speiser DE. Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. Cancer Immunol Immunother 2014 63:247-57; http://www.ncbi.nlm.nih.gov/pubmed/24357148; PMID:24357148; http://dx.doi.org/10.1007/s00262-013-1508-5
- Ng Tang D, Shen Y, Sun J, Wen S, Wolchok JD, Yuan J, Allison JP, Sharma P. Increased Frequency of ICOS+ CD4 T Cells as a Pharmacodynamic Biomarker for Anti-CTLA-4 Therapy. Cancer Immunol Res 2013 1:229-34; http://www.ncbi.nlm.nih.gov/pubmed/24777852; PMID:24777852; http://dx.doi.org/10.1158/2326-6066.CIR-13-0020
- Berman DM, Wolchok J, Weber J, Hamid O, O'Day S, Chasalow SD, Bristol-Myers Squibb, Princeton NJ Memorial Sloan-Kettering Cancer Center, New York, NY; H. Lee Moffitt Cancer Center& Research Institute, Tampa, FL; The Angeles Clinic and Researc N. Association of peripheral blood absolute lymphocyte count (ALC) and clinical activity in patients (pts) with advanced melanoma treated with ipilimumab. J Clin Oncol 2009; 27:Page suppl; abstr 3020; PMID:19470921; http://dx.doi.org/10.1200/JCO.2008.21.1771.
- Cha E, Klinger M, Hou Y, Cummings C, Ribas A, Faham M, Fong L. Improved Survival with T Cell Clonotype Stability After Anti-CTLA-4 Treatment in Cancer Patients. Sci Transl Med 2014 6:238ra70; http://www.ncbi.nlm.nih.gov/pubmed/24871131; PMID:24871131; http://dx.doi.org/10.1126/scitranslmed.3008211
- Robert L, Tsoi J, Wang X, Emerson R, Homet B, Chodon T, Mok S, Huang RR, Cochran AJ, Comin-Anduix B et al. CTLA4 blockade broadens the peripheral T-cell receptor repertoire. Clin Cancer Res 2014 20:2424-32; http://www.ncbi.nlm.nih.gov/pubmed/24583799; PMID:24583799; http://dx.doi.org/10.1158/1078-0432.CCR-13-2648
- Gattinoni L, Klebanoff C a, Palmer DC, Wrzesinski C, Kerstann K, Yu Z, Finkelstein SE, Theoret MR, Rosenberg S a, Restifo NP. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest 2005; 115:1616-26; http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1137001&tool=pmcentrez&rendertype=abstract; PMID:15931392; http://dx.doi.org/10.1172/JCI24480
- Monney L, Sabatos CA, Gaglia JL, Ryu A, Waldner H, Chernova T, Manning S, Greenfield EA, Coyle AJ, Sobel RA et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature 2002 415:536-41; http://www.ncbi.nlm.nih.gov/pubmed/11823861; PMID:11823861; http://dx.doi.org/10.1038/415536a
- Iouzalen N, Andreae S, Hannier S, Triebel F. LAP, a lymphocyte activation gene-3 (LAG-3)-associated protein that binds to a repeated EP motif in the intracellular region of LAG-3, may participate in the down-regulation of the CD3/TCR activation pathway. Eur J Immunol 2001 31:2885-91; http://www.ncbi.nlm.nih.gov/pubmed/11592063; PMID:11592063; http://dx.doi.org/10.1002/1521-4141(2001010)31:10%3c2885::AID-IMMU2885%3e3.0.CO;2-2
- Woo S, Turnis M, Goldberg M, Bankoti J. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res 2012 72:917-27; http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3288154&tool=pmcentrez&rendertype=abstract; PMID:22186141; http://dx.doi.org/10.1158/0008-5472.CAN-11-1620
- Derré L, Rivals J-P, Jandus C, Pastor S, Rimoldi D, Romero P, Michielin O, Olive D, Speiser DE. BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination. J Clin Invest 2010 120:157-67; http://www.jci.org/articles/view/40070/version/2; http://dx.doi.org/10.1172/JCI40070
- Tang AL, Teijaro JR, Njau MN, Chandran SS, Azimzadeh A, Nadler SG, Rothstein DM, Farber DL. CTLA4 expression is an indicator and regulator of steady-state CD4+ FoxP3+ T cell homeostasis. J Immunol 2008; 20:1601-1609; 181:1806-13; http://www.ncbi.nlm.nih.gov/pubmed/2683757; PMID:18641318; http://dx.doi.org/10.4049/jimmunol.181.3.1806
- Weide B, Martens A, Zelba H, Stutz C, Derhovanessian E, Di Giacomo AM, Maio M, Sucker A, Schilling B, Schadendorf D et al. Myeloid-derived suppressor cells predict survival of advanced melanoma patients: comparison with regulatory T cells and NY-ESO-1- or Melan-A-specific T cells. Clin Cancer Res 2013 http://www.ncbi.nlm.nih.gov/pubmed/24323899; PMID:24323899; http://dx.doi.org/10.1200/JCO.2011.40.2271
- Trellakis S, Bruderek K, Hütte J, Elian M, Hoffmann TK, Lang S, Brandau S. Granulocytic myeloid-derived suppressor cells are cryosensitive and their frequency does not correlate with serum concentrations of colony-stimulating factors in head and neck cancer. Innate Immun 2013 19:328-36; http://www.ncbi.nlm.nih.gov/pubmed/23160385; PMID:23160385; http://dx.doi.org/10.1177/1753425912463618
- Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet 2000 356:1795-9; http://www.ncbi.nlm.nih.gov/pubmed/11117911; PMID:11117911; http://dx.doi.org/10.1016/S0140-6736(00)03231-1
- Hayashi T, Imai K, Morishita Y, Hayashi I, Kusunoki Y, Nakachi K. Identification of the NKG2D haplotypes associated with natural cytotoxic activity of peripheral blood lymphocytes and cancer immunosurveillance. Cancer Res 2006 66:563-70; http://www.ncbi.nlm.nih.gov/pubmed/16397273; PMID:16397273; http://dx.doi.org/10.1158/0008-5472.CAN-05-2776
- Lu C, Kerbel RS. Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression. J Cell Biol 1993; 120:1281-8; http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2119719&tool=pmcentrez&rendertype=abstract; PMID:8436594; http://dx.doi.org/10.1083/jcb.120.5.1281
- Soubrane C, Rixe O, Meric J-B, Khayat D, Mouawad R. Pretreatment serum interleukin-6 concentration as a prognostic factor of overall survival in metastatic malignant melanoma patients treated with biochemotherapy: a retrospective study. Melanoma Res 2005 15:199-204; http://www.ncbi.nlm.nih.gov/pubmed/15917702; PMID:15917702; http://dx.doi.org/10.1097/00008390-200506000-00009
- Hoejberg L, Bastholt L, Johansen JS, Christensen IJ, Gehl J, Schmidt H. Serum interleukin-6 as a prognostic biomarker in patients with metastatic melanoma. Melanoma Res 2012 22:287-93; http://www.ncbi.nlm.nih.gov/pubmed/22617301; PMID:22617301; http://dx.doi.org/10.1097/CMR.0b013e3283550aa5
- Tartour E, Blay JY, Dorval T, Escudier B, Mosseri V, Douillard JY, Deneux L, Gorin I, Negrier S, Mathiot C et al. Predictors of clinical response to interleukin-2–based immunotherapy in melanoma patients: a French multiinstitutional study. J Clin Oncol 1996 14:1697-703; http://www.ncbi.nlm.nih.gov/pubmed/8622090; PMID:8622090; http://dx.doi.org/10.1200/JCO.2011.40.2271
- Wang W, Yu D, Sarnaik AA, Yu B, Hall M, Morelli D, Zhang Y, Zhao X, Weber JS. Biomarkers on melanoma patient T cells associated with ipilimumab treatment. J Transl Med 2012 10:146; http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3527361&tool=pmcentrez&rendertype=abstract; PMID:22788688; http://dx.doi.org/10.1186/1479-5876-10-146
- Romano E, Kusio-Kobialka M, Foukas PG, Baumgaertner P, Meyer C, Ballabeni P, Michielin O, Weide B, Romero P, Speiser DE. Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. Proc Natl Acad Sci 2015;112:6140–6145; PMID:25918390; http://dx.doi.org/10.1073/pnas.1417320112
- Himmel ME, MacDonald KG, Garcia R V, Steiner TS, Levings MK. Helios+ and Helios- cells coexist within the natural FOXP3+ T regulatory cell subset in humans. J Immunol 2013 190:2001-8; http://www.ncbi.nlm.nih.gov/pubmed/23359504; PMID:23359504; http://dx.doi.org/10.4049/jimmunol.1201379
- Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, Chen J-F, Enjyoji K, Linden J, Oukka M et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 2007 204:1257-65; http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2118603&tool=pmcentrez&rendertype=abstract; PMID:17502665; http://dx.doi.org/10.1084/jem.20062512
- Thornton AM, Korty PE, Tran DQ, Wohlfert E a, Murray PE, Belkaid Y, Shevach EM. Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells. J Immunol 2010 184:3433-41; http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3725574&tool=pmcentrez&rendertype=abstract; PMID:20181882; http://dx.doi.org/10.4049/jimmunol.0904028
- Sarnaik AA, Yu B, Yu D, Morelli D, Hall M, Bogle D, Yan L, Targan S, Solomon J, Nichol G et al. Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma. Clin Cancer Res 2011 17:896-906; http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3041838&tool=pmcentrez&rendertype=abstract; PMID:21106722; http://dx.doi.org/10.1158/1078-0432.CCR-10-2463
- Simeone E, Gentilcore G, Giannarelli D, Grimaldi AM, Carac∫ C, Curvietto M, Esposito A, Paone M, Palla M, Cavalcanti E et al. Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. Cancer Immunol Immunother 2014 63:675-83; http://www.ncbi.nlm.nih.gov/pubmed/24695951; PMID:24695951; http://dx.doi.org/10.1007/s00262-014-1545-8
- Pico de Coaña Y, Wolodarski M, Gentilcore G, Yoshimoto Y, Poschke I, Hansson J, Masucci G V, Kiessling R. Ipilimumab treatment decreases circulating Tregs and GrMDSC while enhancing CD4+ T cell activation. J Transl Med 2015; 13:O7; http://www.translational-medicine.com/content/13/S1/O7; http://dx.doi.org/10.1186/1479-5876-13-S1-O7
- Idorn M, Køllgaard T, Kongsted P, Sengeløv L, Thor Straten P. Correlation between frequencies of blood monocytic myeloid-derived suppressor cells, regulatory T cells and negative prognostic markers in patients with castration-resistant metastatic prostate cancer. Cancer Immunol Immunother 2014; 63:1177-1187; http://www.ncbi.nlm.nih.gov/pubmed/25085000; PMID:25085000; http://dx.doi.org/10.1007/s00262-014-1591-2
- Mundy-Bosse BL, Young GS, Bauer T, Binkley E, Bloomston M, Bill MA, Bekaii-Saab T, Carson WE, Lesinski GB. Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-α signaling in CD4 + T cells from patients with GI malignancy. Cancer Immunol Immunother 2011; 60:1269-79; PMID:21604071; http://dx.doi.org/10.1007/s00262-011-1029-z
- Chen M-F, Kuan F-C, Yen T-C, Lu M-S, Lin P-Y, Chung Y-H, Chen W-C, Lee K-D. IL-6-stimulated CD11b+ CD14+ HLA-DR- myeloid-derived suppressor cells, are associated with progression and poor prognosis in squamous cell carcinoma of the esophagus. Oncotarget 2014; 5:8716-28; http://www.ncbi.nlm.nih.gov/pubmed/25238263; http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC4226716; PMID:25238263; http://dx.doi.org/10.18632/oncotarget.2368
- Agarwala SS, Keilholz U, Gilles E, Bedikian AY, Wu J, Kay R, Stein CA, Itri LM, Suciu S, Eggermont AMM. LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951). Eur J Cancer 2009 45:1807-14; http://www.ncbi.nlm.nih.gov/pubmed/19419855; PMID:19419855; http://dx.doi.org/10.1016/j.ejca.2009.04.016
- Kelderman S, Heemskerk B, van Tinteren H, van den Brom RRH, Hospers GAP, van den Eertwegh AJM, Kapiteijn EW, de Groot JWB, Soetekouw P, Jansen RL et al. Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. Cancer Immunol Immunother 2014; 63:449-58; http://www.ncbi.nlm.nih.gov/pubmed/24609989; PMID:24609989